Clinical Trial

Ongericimab Injection Reducing Recurrence of Ischemic Stroke

Study acronym: ORIS
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The Oris trial aims to evaluate whether the use of Ongericimab injection in patients with atherosclerotic ischemic cerebrovascular disease within 3 months of onset can reduce the risk of recurrent major cardiovascular events by achieving lower lipid-lowering target values (LDL-C \< 1.4 mmol/L).
Protocol Amendment History 1 change
notable Trial sites expanded: 1 -> 199 locations 2026-04-17
Trial Details
NCT Number NCT07242599
Lead Sponsor Beijing Tiantan Hospital
Conditions Ischemic Cerebral Infarction
Enrollment 4,810 participants
Start Date 2026-04-22
Primary Completion 2029-04-01 (estimated)
Study Completion 2029-04-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-16